Kathy Turner V - 15 Feb 2023 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Reporting relationship: Senior Vice President
Issuer ticker: IDXX
Reported as of: 15 Feb 2023
Net transaction value: -$434,852
SEC form: 4
Accepted by SEC: 17 Feb 2023, 16:04:54 UTC
Prior SEC filing: 16 Feb 2023
Next SEC filing: 08 Apr 2024
Source filing: View source filing
Reporting owner signature: /s/ Lily J. Lu, Attorney-in-Fact for Kathy V. Turner

Key filing fact

Kathy Turner V filed Form 4 for IDEXX LABORATORIES INC /DE (IDXX) on 17 Feb 2023.

Key facts

This page summarizes Kathy Turner V's Form 4 filing for IDEXX LABORATORIES INC /DE (IDXX).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 17 Feb 2023, 16:04.

Change

Previous filing in this sequence was filed on 16 Feb 2023.
Current net transaction value: -$434,852.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IDXX transaction

Common Stock

Award

Transaction value: $79,540
Shares: +1,000
Change %: +14%
Price: $79.54^*
Shares after: 8,380
Date: 15 Feb 2023
Ownership: Direct

IDXX transaction

Common Stock

Sale

Transaction value: $510,031
Shares: -1,000
Change %: -12%
Price: $510.03
Shares after: 7,380
Date: 15 Feb 2023
Ownership: Direct
Footnotes: F1

IDXX transaction

Common Stock

Options Exercise

Transaction value: $795
Shares: +10
Change %: +0.14%
Price: $79.54^*
Shares after: 7,390
Date: 16 Feb 2023
Ownership: Direct

IDXX transaction

Common Stock

Sale

Transaction value: $5,156
Shares: -10
Change %: -0.14%
Price: $515.58
Shares after: 7,380
Date: 16 Feb 2023
Ownership: Direct

IDXX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 100
Date: 15 Feb 2023
Ownership: by spouse
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IDXX transaction Derivative

Non-Qualified Stock Option (right-to-buy)

Options Exercise

Transaction value
Shares: -1,000
Change %: -21%
Price
Shares after: 3,736
Date: 15 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,000
Exercise price: $79.54
Footnotes: F3, F4

IDXX transaction Derivative

Non-Qualified Stock Option (right-to-buy)

Options Exercise

Transaction value
Shares: -10
Change %: -0.27%
Price
Shares after: 3,726
Date: 16 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10
Exercise price: $79.54
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents the weighted average price of the shares sold ranging from a low of $510.00 to a high of $510.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Footnote F2

The reporting person disclaims beneficial interest of the shares of common stock held by her spouse except to the extent of her pecuniary interest therein.

Footnote F3

Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

Footnote F4

Not applicable.